Categories
Change Password!
Reset Password!
OnabotulinumtoxinA
treatment helps to improve sleep quality, reduce fatigue symptoms with promising
effects beyond those of headache frequency reduction, especially in chronic
migraine patients with psychiatric comorbidities.
OnabotulinumtoxinA not only
reduces anxiety, fatigue and depression but also reduces headache frequency and
improve symptoms of poor sleep quality, as per the information gained by a
recent open-label, prospective, multicentre analysis of the Journal of
Neurology, Neurosurgery, and Psychiatry.
A total of nine treatments were
given to patients with chronic migraine (CM) under the Chronic Migraine
OnabotulinumtoxinA Prolonged Efficacy open-Label (COMPEL) study. Efficacy of
OnabotulinumtoxinA on depression and anxiety assessed by applying the
Generalised Anxiety Disorder (GAD-7) and The Patient Health Questionnaire
(PHQ-9) scales, respectively and clinical improvement by the percentage of
participants enduring a ≥1 severity category decrease in GAD-7 and PHQ-9. The Fatigue
Severity Scale and the Pittsburgh Sleep Quality Index were used to measure the
association of onabotulinumtoxinA with fatigue and sleep quality.
A sustained decline in PHQ-9,
GAD-7 scores and headache days were noticed with OnabotulinumtoxinA treatment
over 108 weeks. GAD-7 and PHQ-9 scores were considerably decreased at all time
points among participants with clinically notable signs of anxiety and/or depression
at baseline. Fatigue and sleep quality were also improved, although, limited is
known regarding clinically important changes in these measures. No adverse
effects were noticed during the analysis. These findings demonstrated
Onabotulinumtoxin A as an important treatment regimen for chronic migraine.
The Journal of Neurology, Neurosurgery, and Psychiatry
Effects of onabotulinumtoxin A treatment for chronic migraine on common comorbidities including depression and anxiety
Andrew M Blumenfeld et al.
Comments (0)